Method comparison of dipeptidyl peptidase IV activity assays and their application in biological samples containing reversible inhibitors

被引:71
作者
Matheeussen, Veerle [1 ]
Lambeir, Anne-Marie [1 ]
Jungraithmayr, Wolfgang [2 ]
Gomez, Nelson [3 ]
Mc Entee, Kathleen [3 ]
Van der Veken, Pieter [4 ]
Scharpe, Simon [1 ]
De Meester, Ingrid [1 ]
机构
[1] Univ Antwerp, Med Biochem Lab, B-2020 Antwerp, Belgium
[2] Univ Zurich Hosp, Div Thorac Surg, CH-8091 Zurich, Switzerland
[3] ULB, Fac Med, Physiol Lab, Brussels, Belgium
[4] Univ Antwerp, Med Chem Lab, B-2020 Antwerp, Belgium
关键词
CD26; DPP4; DPPIV inhibitors; Method validation; Preclinical studies; Vildagliptin; DPP-4; INHIBITOR; HIGHLY POTENT; CELL MASS; SITAGLIPTIN; RATS; VILDAGLIPTIN; AMINOPEPTIDASE; PURIFICATION; DISCOVERY; METFORMIN;
D O I
10.1016/j.cca.2011.10.031
中图分类号
R446 [实验室诊断]; R-33 [实验医学、医学实验];
学科分类号
1001 ;
摘要
Background: Dipeptidyl peptidase IV (DPPIV, DPP4) is a serine protease that releases N-terminal dipeptides. It is a validated drug target for type 2 diabetes and DPPIV inhibitors are currently evaluated for other therapeutic applications. Various assays are used for DPPIV activity measurements in biological samples. Highly sensitive methods are needed to measure also very low activities in inhibited samples. Methods: Here, the three most extensively used substrates to quantify DPPIV activity are compared using in-house methods. A luminescent kit was also included. In addition, one of the in-house fluorometric assays was elaborated for use in biological samples containing reversible DPPIV inhibitors to estimate residual DPPIV activity which is usually underestimated due to sample dilution. Results: The in-house methods showed a good precision, linearity and specificity. Both fluorometric substrates had a 10-fold higher sensitivity compared to the colorimetric assay. The luminescent kit was found to be the most sensitive. Conclusions: All three in-house methods can be used to measure DPPIV activity in non-inhibited biological samples. The more sensitive fluorometric assays are recommended when sample volumes are limited or when using inhibited samples. The elaborated fluorometric method can be used to estimate the residual in vivo DPPIV activity in inhibitor treated subjects. (C) 2011 Elsevier B.V. All rights reserved.
引用
收藏
页码:456 / 462
页数:7
相关论文
共 41 条
[1]   Cloning, expression and chromosomal localization of a novel human dipeptidyl peptidase (DPP) IV homolog, DPP8 [J].
Abbott, CA ;
Yu, DMT ;
Woollatt, E ;
Sutherland, GR ;
McCaughan, GW ;
Gorrell, MD .
EUROPEAN JOURNAL OF BIOCHEMISTRY, 2000, 267 (20) :6140-6150
[2]   Discovery and preclinical profile of saxagliptin (BMS-477118): A highly potent, long-acting, orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes [J].
Augeri, DJ ;
Robl, JA ;
Betebenner, DA ;
Magnin, DR ;
Khanna, A ;
Robertson, JG ;
Wang, AY ;
Simpkins, LM ;
Taunk, P ;
Huang, Q ;
Han, SP ;
Abboa-Offei, B ;
Cap, M ;
Xin, L ;
Tao, L ;
Tozzo, E ;
Welzel, GE ;
Egan, DM ;
Marcinkeviciene, J ;
Chang, SY ;
Biller, SA ;
Kirby, MS ;
Parker, RA ;
Hamann, LG .
JOURNAL OF MEDICINAL CHEMISTRY, 2005, 48 (15) :5025-5037
[3]   Disposition of the dipeptidyl peptidase 4 inhibitor sitagliptin in rats and dogs [J].
Beconi, Maria G. ;
Reed, James R. ;
Teffera, Yohannes ;
Xia, Yuan-Qing ;
Kochansky, Christopher J. ;
Liu, David Q. ;
Xu, Shiyao ;
Elmore, Charles S. ;
Ciccotto, Suzanne ;
Hora, Donald F. ;
Stearns, Ralph A. ;
Vincent, Stella H. .
DRUG METABOLISM AND DISPOSITION, 2007, 35 (04) :525-532
[4]   Pharmacokinetic and pharmacodynamic properties of multiple oral doses of sitagliptin, a dipeptidyl peptidase-IV inhibitor: A double-blind, randomized, placebo-controlled study in healthy male volunteers [J].
Bergman, AJ ;
Stevens, C ;
Zhou, YY ;
Yi, BM ;
Laethem, M ;
De Smet, M ;
Snyder, K ;
Hilliard, D ;
Tanaka, W ;
Zeng, W ;
Tanen, M ;
Wang, AQ ;
Chen, L ;
Winchell, G ;
Davies, MJ ;
Ramael, S ;
Wagner, JA ;
Herman, GA .
CLINICAL THERAPEUTICS, 2006, 28 (01) :55-72
[5]   STATISTICAL METHODS FOR ASSESSING AGREEMENT BETWEEN TWO METHODS OF CLINICAL MEASUREMENT [J].
BLAND, JM ;
ALTMAN, DG .
LANCET, 1986, 1 (8476) :307-310
[6]   Inhibition of dipeptidyl-peptidase IV catalyzed peptide truncation by vildagliptin ((2S)-{[3-hydroxyadamantan-1-yl) amino]acetyl}-pyrrolidine-2-carbonitrile) [J].
Brandt, I ;
Joossens, J ;
Chen, X ;
Maes, MB ;
Scharpé, S ;
De Meester, I ;
Lambeir, AM .
BIOCHEMICAL PHARMACOLOGY, 2005, 70 (01) :134-143
[7]   Long-term inhibition of dipeptidyl peptidase-4 in Alzheimer's prone mice [J].
D'Amico, Michele ;
Di Filippo, Clara ;
Marfella, Raffaele ;
Abbatecola, Angela Maria ;
Ferraraccio, Franca ;
Rossi, Francesco ;
Paolisso, Giuseppe .
EXPERIMENTAL GERONTOLOGY, 2010, 45 (03) :202-207
[8]   Dipeptidyl peptidases and related proteins: multifaceted markers and therapeutic targets [J].
De Meester, Ingrid ;
Scharpe, Simon ;
Lambeir, Anne-Marie .
CLINICAL CHEMISTRY AND LABORATORY MEDICINE, 2009, 47 (03) :245-247
[9]   Dipeptidyl peptidase-4 inhibitors in the treatment of type 2 diabetes: a comparative review [J].
Deacon, C. F. .
DIABETES OBESITY & METABOLISM, 2011, 13 (01) :7-18
[10]   Use of immobilized adenosine deaminase (EC 3.5.4.4) for the rapid purification of native human CD26 dipeptidyl peptidase IV (EC 3.4.14.5) [J].
DeMeester, I ;
Vanhoof, G ;
Lambeir, AM ;
Scharpe, S .
JOURNAL OF IMMUNOLOGICAL METHODS, 1996, 189 (01) :99-105